Bleeding Events After Triple Antithrombotic Therapy Initiation.

Bleeding Events After Triple Antithrombotic Therapy Initiation: a Prospective Observational Study in Real Life

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03203980

Acronym

HEMOTRI

Enrollment

200

Registered

2017-06-29

Start date

2017-07-15

Completion date

2018-07-15

Last updated

2017-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding

Brief summary

The optimal antithrombotic therapy for patients requiring anticoagulation after coronary stenting is unknown. Double platelets suppressive agents combined with oral anticoagulation (triple antithrombotic therapy) remains the Gold standard. Our study aims at studying bleeding events occurring until 6 months after the initiation of triple antithrombotic therapy.

Interventions

OTHERTriple antithrombotic therapy

patients who are prescribed double antiplatelets agents and oral anticoagulation (except VKA)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* patients requiring triple antithrombotic therapy, including double antiplatelets agents and oral anticoagulation

Exclusion criteria

* history of bleeding * patients already under triple antithrombotic therapy * patients under vitamin K antagonists

Design outcomes

Primary

Measure	Time frame	Description
Bleeding events	within 6 months since the initiation of triple antithrombotic therapy	Bleeding events with clinical significance

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026